As of 2025-06-21, the Intrinsic Value of Anika Therapeutics Inc (ANIK) is 4.10 USD. This Anika valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 10.59 USD, the upside of Anika Therapeutics Inc is -61.30%.
The range of the Intrinsic Value is 3.63 - 10.79 USD
Based on its market price of 10.59 USD and our intrinsic valuation, Anika Therapeutics Inc (ANIK) is overvalued by 61.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 3.63 - 10.79 | 4.10 | -61.3% |
| DCF (Growth 10y) | 6.27 - 48.89 | 9.12 | -13.9% |
| DCF (EBITDA 5y) | 8.31 - 10.03 | 9.24 | -12.7% |
| DCF (EBITDA 10y) | 10.12 - 13.11 | 11.66 | 10.1% |
| Fair Value | -19.79 - -19.79 | -19.79 | -286.83% |
| P/E | (38.23) - (65.45) | (53.82) | -608.2% |
| EV/EBITDA | 5.56 - 9.36 | 7.08 | -33.1% |
| EPV | 18.35 - 23.78 | 21.06 | 98.9% |
| DDM - Stable | (43.94) - (277.39) | (160.67) | -1617.1% |
| DDM - Multi | 3.38 - 17.51 | 5.77 | -45.5% |
| Market Cap (mil) | 151.86 |
| Beta | 0.92 |
| Outstanding shares (mil) | 14.34 |
| Enterprise Value (mil) | 98.49 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.53% |
| Cost of Debt | 5.00% |
| WACC | 5.60% |